Daniala L Weir1,2, Michal Abrahamowicz2,3, Marie-Eve Beauchamp3, Dean T Eurich4,5. 1. Clinical and Health Informatics Research Group, Department of Medicine, McGill University, Montreal, Canada. 2. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada. 3. Centre for Health Outcomes Research, Research Institute of the McGill University Health Centre, Montreal, Canada. 4. School of Public Health, University of Alberta, Edmonton, Canada. 5. Alliance for Canadian Health Outcomes Research in Diabetes, University of Alberta, Edmonton, Canada.
Abstract
AIMS: To evaluate the association between metformin use and heart failure (HF) exacerbation in people with type 2 diabetes (T2D) and pre-existing HF using alternative exposure models. MATERIALS AND METHODS: We analysed data for patients with T2D and incident HF from a national US insurance claims database. We compared the results of several multivariable Cox models where time-varying use of metformin was modelled as: (1) current use; (2) total duration of past use; and (3) use within the past 30 days or 10 days. The outcome was defined as time to HF-related hospitalization. We then re-analysed the data using flexible weighted cumulative exposure (WCE) models. RESULTS: A total of 7620 patients with diabetes and incident HF were analysed. The mean (SD) patient age was 54 (8) years, and 58% (n = 4440) were men. In all, 3799 individuals (50%) were exposed to metformin, and 837 HF hospitalizations (11%) occurred (mean follow-up 1.7 years). Results of conventional models suggested potential acute benefits in reducing HF exacerbation with metformin use in the past 10 days (adjusted hazard ratio [aHR] 0.76, 95% confidence interval [CI] 0.60-0.97), while WCE models, which provided a better fit for the data, suggested lack of a systematic effect (aHR 0.91, 95% CI 0.69-1.20). CONCLUSIONS: Our results suggest that cumulative metformin exposure does not decrease the risk of HF-related exacerbation. Use of other anti-hyperglycaemic agents with proven efficacy in patients with HF should also be considered as treatment options in this population.
AIMS: To evaluate the association between metformin use and heart failure (HF) exacerbation in people with type 2 diabetes (T2D) and pre-existing HF using alternative exposure models. MATERIALS AND METHODS: We analysed data for patients with T2D and incident HF from a national US insurance claims database. We compared the results of several multivariable Cox models where time-varying use of metformin was modelled as: (1) current use; (2) total duration of past use; and (3) use within the past 30 days or 10 days. The outcome was defined as time to HF-related hospitalization. We then re-analysed the data using flexible weighted cumulative exposure (WCE) models. RESULTS: A total of 7620 patients with diabetes and incident HF were analysed. The mean (SD) patient age was 54 (8) years, and 58% (n = 4440) were men. In all, 3799 individuals (50%) were exposed to metformin, and 837 HF hospitalizations (11%) occurred (mean follow-up 1.7 years). Results of conventional models suggested potential acute benefits in reducing HF exacerbation with metformin use in the past 10 days (adjusted hazard ratio [aHR] 0.76, 95% confidence interval [CI] 0.60-0.97), while WCE models, which provided a better fit for the data, suggested lack of a systematic effect (aHR 0.91, 95% CI 0.69-1.20). CONCLUSIONS: Our results suggest that cumulative metformin exposure does not decrease the risk of HF-related exacerbation. Use of other anti-hyperglycaemic agents with proven efficacy in patients with HF should also be considered as treatment options in this population.
Authors: Mohapradeep Mohan; Shaween Al-Talabany; Angela McKinnie; Ify R Mordi; Jagdeep S S Singh; Stephen J Gandy; Fatima Baig; Muhammad S Hussain; U Bhalraam; Faisel Khan; Anna-Maria Choy; Shona Matthew; John Graeme Houston; Allan D Struthers; Jacob George; Chim C Lang Journal: Eur Heart J Date: 2019-11-01 Impact factor: 35.855
Authors: Jessica Phillips; Camille Akemann; Jeremiah N Shields; Chia-Chen Wu; Danielle N Meyer; Bridget B Baker; David K Pitts; Tracie R Baker Journal: Environ Toxicol Pharmacol Date: 2021-07-24 Impact factor: 5.785
Authors: Eilon Ram; Jacob Lavee; Alexander Tenenbaum; Robert Klempfner; Enrique Z Fisman; Elad Maor; Tal Ovdat; Sergei Amunts; Leonid Sternik; Yael Peled Journal: Cardiovasc Diabetol Date: 2019-09-16 Impact factor: 9.951